SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Genetronics Biomedical Corporation , a leader in cancer and other medical therapies based on electroporation-enhanced delivery of drugs, DNA vaccines and genes, is presenting a poster in association with Chiron Corporation disclosing results and conclusions achieved under a continuing research collaboration between the companies. The poster, entitled "Toward the Development of Electroporation for Delivery of DNA Vaccines to Humans," is being presented at the 7th Annual Meeting of the American Society of Gene Therapy (ASGT), which is taking place June 2-6, 2004, in Minneapolis, Minnesota.
The poster presents results and conclusions including:
* Data from a series of preclinical studies in large animals, including
non-human primates, using electroporation-enhanced DNA vaccination for
potential treatment of infectious diseases such as HIV.
* Results demonstrating the effectiveness of in vivo electroporation for
increasing the potency of DNA vaccines in non-human primates. The use
of electroporation provided faster, stronger, and longer-lasting
antibody and cellular immune responses.
* Results indicating that an electroporation regimen using Genetronics'
advanced electroporation technology provided antibody levels in
rabbits equivalent to levels of more invasive, earlier-generation
electroporation equipment. Genetronics' innovations include fewer
needles, reduced electrode toxicity, and fewer electrical pulses.
This new electroporation mode has the potential for routine use in the
clinical delivery of therapeutic vaccines.
"These experimental results, as well as results from other ongoing studies of large animals by the company, continues to validate the ability of electroporation to enhance the efficacy of DNA vaccines that have tremendous potential as new therapeutic and prophylactic agents to treat various diseases," said Dr. Avtar Dhillon, Genetronics' CEO & President.
About the American Society of Gene Therapy (ASGT)
ASGT is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene therapies. ASGT is committed to promoting and fostering the exchange and dissemination of information and ideas related to gene therapy, encouraging the general field of research involving gene therapy and promoting professional and public education in all areas of gene therapy. ASGT has an official journal, Molecular Therapy, which publishes scientific meritorious papers in the areas of gene transfer, gene regulation, gene discovery, cell therapy, experimental models, correction of genetic and acquired diseases, and clinical trials. ASGT holds an annual meeting each year, featuring scientific symposia, workshops, oral abstract presentations, exhibits and poster sessions. For more information, go to http://www.asgt.org/.
About Genetronics Biomedical Corporation
Genetronics Biomedical Corporation is a late stage biomedical company primarily focused on building an oncology franchise based on its proprietary electroporation therapy (EPT). EPT enhances the local delivery of drugs, DNA vaccines, and genes. The company is moving its lead product, MedPulser(R), through pre-marketing studies for head and neck cancer and cutaneous tumors in Europe, where it has received CE Mark accreditation, and a Phase III study for recurrent head and neck cancer in the US. EPT can be used to enhance the delivery of other molecules, and the company is developing therapies using DNA vaccines and gene therapies with various biotechnology and pharmaceutical companies. Current partnerships and collaborations include Merck, Chiron, the US Navy and Vical. Genetronics is a leader in electroporation, with over 240 patents issued, allowed or pending. More information can be obtained at http://www.genetronics.com/.
This press release contains certain forward-looking statements relating to Genetronics' plans to develop its electroporation drug and gene delivery technology and to maximize shareholder value. Actual events or results may differ from Genetronics' expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Genetronics' technology by potential corporate partners, and capital market conditions, and others set forth in the Genetronics Annual Report, on Form 10-K for the 12-month period ending December 31, 2003, and the Form 10-Q for the 3-month period ending March 31, 2004, and other regulatory filings. There can be no assurance that any product in the Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market Licensed Products. The American Stock Exchange has not reviewed and do not accept responsibility for the adequacy or accuracy of this release.
Genetronics Biomedical Corporation